创新药BD交易纪录再次刷新，恒生创新药ETF（159316）全天获近亿份净申购

Group 1 - The pharmaceutical sector experienced a collective pullback, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 2.3%, the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index down by 1.8%, and the CSI 300 Pharmaceutical and Health Index down by 1.0% [1] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of nearly 100 million units today, accumulating over 900 million yuan in inflows this month, ranking it among the top in Hong Kong's innovative drug-related products [1] - In a significant development, Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical, involving three products, including two in the research pipeline and one exclusive option. Innovent secured a $1.2 billion upfront payment, with the total deal amount reaching $11.4 billion, setting a record for BD transactions in China's pharmaceutical industry [1]